NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Forecast & News

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HTGM stock has decreased by 13.3% and is now trading at $0.3419. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HTG Molecular Diagnostics.

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for HTG Molecular Diagnostics.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) announced its quarterly earnings results on Wednesday, March, 25th. The medical research company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. HTG Molecular Diagnostics had a negative net margin of 100.45% and a negative return on equity of 96.67%. View HTG Molecular Diagnostics' earnings history.

HTG Molecular Diagnostics issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.2-19.2 million, compared to the consensus revenue estimate of $19.38 million.

4 equities research analysts have issued twelve-month target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $0.70 to $6.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $2.43 in the next twelve months. This suggests a possible upside of 609.3% from the stock's current price. View analysts' price targets for HTG Molecular Diagnostics.

Media headlines about HTGM stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. HTG Molecular Diagnostics earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutHTG Molecular Diagnostics.

Some companies that are related to HTG Molecular Diagnostics include Arrayit (ARYC), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Aurinia Pharmaceuticals (AUPH), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Gilead Sciences (GILD), MEI Pharma (MEIP), Marinus Pharmaceuticals (MRNS), Resonant (RESN) and FleetMatics Group (FLTX).

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (4.35%), Cowen Prime Services LLC (3.68%), Geode Capital Management LLC (0.66%) and HighMark Wealth Management LLC (0.33%). View institutional ownership trends for HTG Molecular Diagnostics.

HTGM stock was purchased by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, HighMark Wealth Management LLC, Perkins Capital Management Inc., and Geode Capital Management LLC. View insider buying and selling activity for HTG Molecular Diagnostics.

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HTGM stock can currently be purchased for approximately $0.34.

HTG Molecular Diagnostics has a market capitalization of $19.84 million and generates $19.20 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe. View additional information about HTG Molecular Diagnostics.

The official website for HTG Molecular Diagnostics is http://www.htgmolecular.com/.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.